J&J settlement offer rejected

The US Justice Department has rejected a $1 billion settlement offer by Johnson & Johnson over allegations that it marketed Risperdal for unapproved uses.

The US Justice Department has rejected a $1 billion settlement offer by Johnson & Johnson over allegations that it marketed Risperdal for unapproved uses.

Various media outlets are reporting that the federal government is instead asking for $1.8 billion to settle civil claims by the government and others over the alleged unsanctioned marketing.

Risperdal and its generic forms are approved by the Food & Drug Administration for use in treatment of bipolar disorder, schizophrenia, and autism. Lawsuits by state and federal governments claim Johnson & Johnson has marketed Risperdal for unapproved uses, such as for the treatment of dementia in the elderly.

J&J has already paid out millions after lawsuits over the allegations, including $158 million to Texas, $327 million to South Carolina, and $258 million to Louisiana.

Al Wasilewski, a J&J press officer, told PRWeek that the company is not putting a communications plan in place to discuss the matter with the public, and it does not plan to comment on the case.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in